IQVIA has entered a long-term partnership with Clalit Health Services to open the first PRIME SITE in Israel.

The alliance will merge the expertise of IQVIA and Clalit in clinical trial delivery, real-world research, data, and genomics. 

With these merged capabilities, the partnership will aid in focusing on the future of innovation, including precision treatment and data-powered clinical trial delivery.

IQVIA Europe, Middle East, Africa, and South Asia president Alistair Grenfell said: “IQVIA is excited to launch its first Prime Site in Israel with such an innovative and well-established healthcare organisation as Clalit. 

“The work done through this collaboration will transform healthcare and pharmaceutical research for Israel and the world, ultimately improving outcomes for patients.”

With the Connected Intelligence of IQVIA and Clalit’s aim to transform data insights based on electronic medical records into enhanced policy and healthcare, the alliance helps IQVIA in meeting pharma interest in the country as a premier stop for innovation and research. 

The Prime Site also guarantees that the organisation can provide Israeli pharma and biotech firms with an in-country solution.

Clalit Health Services acting general director Eli Cohen said: “As the largest health organisation in Israel, Clalit will now leverage its Prime Site designation to allow our patients access to the most advanced therapies being developed. 

“Through the utilisation of data and strategic delivery of research and care, our work together will help unlock further understanding of pharmaceutical and healthcare developments in the real world.”

Clalit operates a network of 14 hospitals and more than 1,600 primary care clinics.

In June last year, IQVIA unveiled the Clinical Data Analytics Suite, a software as a service-based (SaaS) clinical data analytics platform for quicker and smarter trials.